Phanes Therapeutics' CD73 Monoclonal Antibody PT199 Receives CDE Approval to Initiate Clinical Trials in China

On November 28, the CDE official website showed that Phanes Therapeutics, Inc. submitted the clinical trial application for PT199, which has been accepted.

PT199 is a CD73 monoclonal antibody with a differentiated mechanism of action, designed to counter adenosine-mediated immunosuppressive tumor microenvironments.

PT199 can completely inhibit both soluble and cell membrane-bound CD73, which is different from other inhibitors that do not fully suppress CD73. Moreover, at higher concentrations, PT199 does not lose its inhibitory effect or exhibit a "hook effect." Therefore, PT199 overcomes the limitations of many current CD73 inhibitors, with the potential to enhance anti-tumor immune activity and offer a new therapeutic option for cancer patients.

PT199 was approved by the U.S. Food and Drug Administration (FDA) in 2022 to conduct a multi-center clinical Phase I trial in the United States.